Received March 19, 2020
Accepted September 20, 2020

Objective: To investigate if high anti-Müllerian hormone (AMH) concentration is a useful tool to predict the outcome of assisted reproductive treatment. Materials: Retrospective cohort study involving 520 patients who underwent IVF/ICSI procedures were recruited from within a university hospital. Serum AMH level was measured on day 3 of the menstrual cycle. Based on AMH levels, patients were divided into three groups as follows: low (<25th percentile) AMH group, average (25th to 75th percentile) AMH group and high (>75th percentile) AMH group. Fertilization rate (FR), number of oocytes retrieved, number of good quality embryos (GQEs) and clinical pregnancy rate (CPR) were recorded. Results: No difference found between the three AMH groups in terms of maternal age, BMI, FSH, E2, LH and T in IVF/ICSI cycles. Women in high serum AMH group was more number of retrieved oocytes than those in the low or average AMH groups (p < 0.01) in IVF/ICSI cycles; Compared with the low or average AMH groups, women with high AMH had moreGQEs (p < 0.01). However, high AMH women had no significantly greaterCPR compared to women in the low or average AMH groups. In addition, for the prediction of CPR, AMH level alone was found to be not an independent predictor of CPR for IVF and ICSI cycles in the ROC curve analysis. Conclusion: High anti-müllerian hormone levels are an independent predictor of number of retrieved oocytes and good quality embryos (GQEs), but might not reflect the chance of clinical pregnancy rate (CPR) in IVF/ICSI treatment.